Outcomes of Weekly Adalimumab Treatment in Refractory Pediatric Uveitis

Overview

This study evaluates the clinical outcomes of escalating to weekly adalimumab (ADA) in children with refractory non-infectious pediatric uveitis. It highlights the role of serum drug concentrations and anti-adalimumab antibodies in guiding treatment decisions.

Background

Pediatric chronic non-infectious anterior uveitis (pCAU) can lead to severe ocular complications and is often associated with juvenile idiopathic arthritis (JIA). Standard treatment involves systemic immunosuppressive therapy, with adalimumab being a key biologic agent approved for this condition. Despite its efficacy, some patients remain refractory to standard biweekly dosing, prompting the exploration of weekly dosing as a potential escalation strategy.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• Weekly adalimumab dosing is being increasingly considered for refractory pediatric uveitis.
• Escalation to weekly dosing may improve clinical outcomes in patients inadequately controlled on biweekly dosing.
• Serum drug levels and anti-adalimumab antibody titres can inform treatment decisions.
• Adalimumab has been shown to effectively control intraocular inflammation and reduce reliance on corticosteroids.
• Retrospective studies indicate promising outcomes for patients with refractory uveitis when switching to weekly dosing.

Clinical Implications

Clinicians should consider weekly adalimumab dosing for pediatric patients with refractory pCAU who do not respond adequately to biweekly treatment. Monitoring serum drug levels and antibody titres may enhance treatment personalization and efficacy.

Conclusion

The findings support the potential benefits of weekly adalimumab dosing in managing refractory pediatric uveitis, warranting further investigation in larger, controlled studies.

Related Resources & Content

1. Clinical Rheumatology, 2008 -- A Pilot Open-Label Study Assessing Adalimumab's Efficacy in Rheumatoid Arthritis Patients with Prior Infliximab Treatment: Correlation with Reasons for Treatment Failure and Anti-Infliximab Antibody Levels
2. Clinical Rheumatology, 2014 -- Efficacy, safety, and pharmacokinetic profile of adalimumab in young children aged 2 to 4 with polyarticular juvenile idiopathic arthritis
3. Clinical Rheumatology, 2025 -- Evaluating the Role of Early Therapeutic Drug Monitoring of Adalimumab in Predicting Treatment Outcomes and Immunogenicity in Rheumatic Disorders
4. Retinal Physician, 2015 -- Emerging Therapies for Noninfectious Uveitis
5. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis - PMC
6. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis | New England Journal of Medicine
7. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment | Pediatric Rheumatology | Springer Nature Link
8. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis - PMC
9. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis | New England Journal of Medicine
10. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment | Pediatric Rheumatology | Springer Nature Link